EGFR and neoplasm: As a proof-of-principle study, we translated this mechanism to the treatment of OSCC tongue orthotopic xenografts and EGFR-positive PDX models by NP-delivered siLCN2, which effectively inhibited tumor progression and cervical lymphatic metastasis.